Rhenman & Partners Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-73,000	Closed	-$2.56M	–	98
2015 Q4	$2.56M	Buy	73,000 +30,000	+70%	+$1.93M	0.39%	77
2015 Q3	$3.95M	Sell	43,000 -17,765	-29%	-$1.54M	0.63%	58
2015 Q2	$5.34M	Buy	60,765 +6,765	+13%	+$579K	0.64%	55
2015 Q1	$4.01M	Sell	54,000 -31,398	-37%	-$2.22M	0.68%	51
2014 Q4	$4.78M	Buy	85,398 +28,398	+50%	+$1.49M	1.39%	23
2014 Q3	$2.59M	Sell	57,000 -33,000	-37%	-$1.38M	0.76%	48
2014 Q2	$3.73M	Buy	+90,000	New	+$4.64M	1.11%	29

Other funds holding CLVS

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Rhenman & Partners Asset Management's CLVS Position: Q1 2016 in Review

Rhenman & Partners Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q1 2016, closing a stake of 73,000 shares — an estimated $2.56M sold.

Rhenman & Partners Asset Management first reported a position in CLVS in Q2 2014 and held it in 7 quarters. The position peaked at $5.34M in Q2 2015. 135 funds tracked by Wall St. Rank hold CLVS as of Q1 2016.

Rhenman & Partners Asset Management reported no remaining Clovis Oncology, Inc. position as of Q1 2016 after selling out during the quarter.
Rhenman & Partners Asset Management sold 73,000 Clovis Oncology, Inc. shares in Q1 2016, an estimated $2.56M.
Rhenman & Partners Asset Management first reported a position in Clovis Oncology, Inc. in Q2 2014 and held it in 7 quarters.
Rhenman & Partners Asset Management's Clovis Oncology, Inc. position peaked at $5.34M in Q2 2015.
135 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2016.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2016, filed 19 Apr 2016.